At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 168 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
In plain English
The Oxford Risk Factors And Non-Invasive Imaging Study is looking at cardiovascular diseases (problems affecting the heart and blood vessels) and risk factors for them. It is run by the University of Oxford. The study is listed as recruiting people aged 18 to 99.
Who can take part
- For study arms 1, 2 and 3: you must be willing and able to give informed consent to take part.
- For study arms 1, 2 and 3: male or female, aged 18 to 99 years.
- For study arm 4: male or female, aged 18 to 99 years.
Who may not be able to
- For study arms 1, 2 and 3: unable or unwilling to give consent.
- For study arms 1, 2 and 3: active cancer.
- For study arm 4: taking part in study arms 1, 2 or 3.
- For study arm 4: you have already opted out of your data being used for research.
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Years to 99 Years
- Who
- All
- Number of participants
- 250,000
- Started
- 2016-02-23
- Last checked
- 2024-12
Plain English Summary
What is this study?
- • Testing a new treatment for cardiovascular diseases
- • Clinical study - 250,000 participants
- • ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk
Who can take part?
- • Ages 18 Years to 99 Years
- • Diagnosed with cardiovascular diseases
Where?
- • Bath - Royal United Hospitals Bath NHS Foundation Trust
- • Birmingham - Sandwell and West Birmingham Hospitals NHS Trust
- • Birmingham - University Hospitals Birmingham NHS Trust
- • Cambridge - Royal Papworth Hospital NHS Trust
- • +14 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.
More detail
The ORFAN registry will include unselected, consecutive patients undergoing CT scans (coronary CT angiograms (CCTA), CT chest, abdomen and pelvis scans) collected at the participating centres. The study will combine imaging data with patient demographics and clinical information (including prospective outcomes) to aid the development and/or validation of new or existing image analysis algorithms and software tools to improve diagnosis, clinical risk discrimination and prediction. Specifically, ORFAN will evaluate the specificity, utility and predictive value of newly developed image analysis methods. ORFAN will recruit and follow-up patients prospectively, linking the index CT scan with blood biomarkers, genetic information as well as information on disease progression (recorded through follow-up CT scans) and clinical outcomes data. The study will also collect CT scans performed in the past and link them with clinical factors and prospective outcomes data collected after the index scan was performed.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 99 Years
- Who can join: All genders
What the study is looking for
- ✓Inclusion Criteria for study Arms 1, 2 and 3:
- ✓Participant is willing and able to give agreement to take part for participation in the study.
- ✓Male or Female, aged 18 -99 years.
- ✓Inclusion Criteria for study Arm 4:
Who cannot take part
- ✗Exclusion Criteria for Study Arms 1, 2 and 3:
- ✗Unable or unwilling to consent
- ✗Active cancer
- ✗Exclusion Criteria for Study Arm 4:
- ✗Participation in Study Arms 1, 2 or 3
See the full criteria
Where Is This Study? (18 UK sites)
Royal United Hospitals Bath NHS Foundation Trust
Bath, United Kingdom
Sandwell and West Birmingham Hospitals NHS Trust
Birmingham, United Kingdom
University Hospitals Birmingham NHS Trust
Birmingham, United Kingdom
Royal Papworth Hospital NHS Trust
Cambridge, United Kingdom
University of Edinburgh, Royal Infirmary
Edinburgh, United Kingdom
Golden Jubilee National Hospital
Glasgow, United Kingdom
NHS Greater Glasgow and Clyde
Glasgow, United Kingdom
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
University Hosptials of Leicester NHS Trust
Leicester, United Kingdom
Carolyn Maloney
uhl-tr.researchandinnovationadminmailbox@nhs.net0116 258 8351Liverpool heart and chest hospital
Liverpool, United Kingdom
Barts Health NHS Trust
London, United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
Royal Brompton and Harefield Hospitals
London, United Kingdom
University Hospital of Manchester NHS Foundation Trust
Manchester, United Kingdom
Milton Keynes University Hospital
Milton Keynes, United Kingdom
The Newcastle Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Heart and Lung Centre, New Cross Hospital
Wolverhampton, United Kingdom
How to Get in Touch
Kenneth Chan, Dr
Sponsor contactCONTACT
Ahmad Abdullrahman, Dr
Sponsor contactCONTACT